Our bodies are an intricate network of interconnected systems, each playing a vital role in maintaining our overall health. One player is copper, a trace element that has been found to regulate important processes like energy metabolism, antioxidation, and coagulation.
Maintaining a balance of copper ions in our bodies is vital to prevent health issues like atherosclerosis and cardiovascular diseases.
Scientists and healthcare professionals are struggling with the possible harm caused by copper metabolism imbalance in cells, potentially leading to cytotoxic effects.
This issue is being tackled in the emerging field of copper metabolism regulation, which recently made a breakthrough with the identification of a novel regulatory cell death mode, “cuprotosis.”
What Exactly is Cuprotosis?
At the Broad Institute of MIT and Harvard, researchers led by Peter Tsvetkov and Todd Golub, have made a significant discovery in the field of nanoscience. They found that copper, a common metal, can trigger a specific type of cell death named “cuproptosis”.
Cuprotosis is a newly identified type of cell death caused by excess copper ions. These ions interact with specific proteins in the mitochondria, the cell’s energy-producing component. This interaction triggers a chain reaction that leads to protein build-up and cellular stress, ultimately resulting in cell death.
The team conducted numerous experiments using a compound called elesclomol. They noticed that when they removed serum, which is like food for cells that contain copper, cells became stronger and could resist the effects of elesclomol. But when they added copper into the mix, the cells became very sensitive to elesclomol and started to die.
Interestingly, this wasn’t just about elesclomol. Their investigations extended into the realm of nanoscience as they discovered that other compounds, like disulfiram and NSC319726, also caused cells to die when copper was present. This unique interaction was specific to copper and didn’t occur with other metals like iron, cobalt, zinc, and nickel. They also discovered that they could control this cell death if they added substances that can grab and hold onto copper, called chelators.
Tsvetkov, Golub, and their team noted that cells that rely heavily on mitochondrial metabolism were more sensitive to these copper compounds. This was in contrast to cells that get their energy from another process called glycolysis.
To delve further into this mystery, the team performed genome-wide screening, a deep-dive into our DNA, aided by tools and techniques from the nanoscience field. They identified seven key genes that control cuproptosis. One of these genes, called FDX1, was particularly crucial. When they turned off FDX1, it stopped cell death from happening.
The scientists didn’t limit their research to the lab. They also conducted experiments on cells with varying levels of copper. They found that cells were more likely to die when there was more copper. They observed the same thing in mice with a disease, causing an excess of copper in their bodies.
This innovative research by the team at the Broad Institute, driven by the principles of nanoscience, is critical because it deepens our understanding of how cells die. This could have significant implications for diseases like cancer.
Undoubtedly, many questions remain. They’re pondering things like how much copper is needed to trigger cell death, how this process is regulated, and if we can use this knowledge to devise new cancer treatments. But every significant discovery starts with a single step, and this team has indeed taken a giant leap.
The significance of their groundbreaking findings cannot be overstated, especially considering the rapidly growing cell culture market, which their work has the potential to revolutionise.
According to Precedence Research, the global market for cell culture is projected to exceed an approximate value of US$ 52.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.21%.
The report said, “The rapidly growing biopharmaceutical industry is boosting the demand for the cell culture techniques.”
Overcoming Challenges in Implementing Novel Treatment Methods
Nonetheless, this development comes with its own set of challenges.
There are regulatory hurdles to navigate, high research and development costs to account for, and the need to demonstrate the efficacy and safety of the new treatment methods. Additionally, the established interests of existing healthcare and pharmaceutical companies may pose potential barriers to entry.
This being said, companies like Wilson Therapeutics, backed by a total funding amount of $40 million, are leveraging copper in their treatment methods.
They’re in the process of developing therapies to combat Wilson Disease, a rare genetic disorder characterised by an excessive copper buildup in the body. Their primary product, WTX101, aims to rid the body of surplus copper, predominantly through bile, a process that’s hindered in patients suffering from this disease.
Conclusion
Looking ahead, the sector promises continued growth and development. As more research is conducted into cuprotosis and its potential applications, we can expect the arrival of more targeted therapies and personalised treatment strategies. The future appears bright for those willing to invest in the exploration and application of copper in human health.
Source/Image
